CTOs on the Move

InflaRx

www.inflarx.com

 
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imprimis Pharmaceuticals

Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices. We are pioneering a new commercial pathway in the pharmaceutical industry, using compounding pharmacies for the formulation and distribution of high quality, proprietary formulations that are supported by the clinical experience of physicians and their patients. We are focused on ophthalmology and urology drug therapies; however we also sell other formulations outside of our core ophthalmology and urology therapeutic areas. All of our innovative drug formulations are born from the clinical experience of physician prescribers and pharmacist formulators. We believe our unique business model provides us with the opportunity to address unmet patient needs while delivering safe, near-term and affordable medical solutions to Americans. We have made tremendous progress since the launch of our ophthalmology business and our Go Dropless™ educational campaign in April 2014. Our ophthalmology business is disrupting the billion dollar eye drop market as physicians are adopting Dropless Therapy™ for their patients. We recently announced the availability of our LessDrops™ proprietary topical combination eye drops for post LASIK and other ocular surgeries. During first quarter 2015, we launched our urology business, entering the multi-billion dollar interstitial cystitis (IC) market. In connection with our urology launch, we will commercialize our patented Hep-Lido-A formulation and promote the Defeat IC™ educational campaign focused on medical practitioners and the estimated ten million women and men in the U.S. chronically affected by IC and PBS. We are committed to customer relations, highest quality standards, accessible innovation and solving the unmet needs in the markets we serve. We are delivering on the promise of our unique model and look forward to continuing to serve the needs of our customers with additional novel drug therapies in our product portfolio, and in turn grow our business. Our hope is that through the success of our business we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.

DeliverIt Pharmacy

The new and innovated concept of DeliverIt Pharmacy came from our 20 years of experience. We have seen it all, the frustrations and hassles customers have to go through just to get their prescription. At DeliverIt Pharmacy we strive to keep the balance of affordable and convenience for our customers while performing proficiently and efficiently. We conveniently offer a variety of ways for you to get your prescription such as delivery, drive-thru, and walk-in pickup so there`s no frustrating long-lines to wait in. This will allow you to spend more time with your family, or return to your busy schedule of work or school! We offer compounding, which allows us to work with your physician to customized your prescription to your individual needs. We care for your love one`s well-being just as much as you do! Whether it`s your children, parents, or pets! We offer a variety of methods to make it easier for you to get them to comply with their medication

ASP Events

Advanced Sterilization Products (ASP) your leaders in sterilization. To protect patients during their most critical moments | Homepage | Irvine CA United States

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.